Clinically meaningful improvements in global IBS symptom severity observed as early as Week 1 and sustained through Week 7, with EBX-102-02 outperforming placebo throughout …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
